“The FDA is alerting health care providers and consumers about the possibility of rare, but serious, injuries that may occur due to unintentional injection of soft tissue filler into blood vessels in the face”.
New labeling requirements have been implemented by the FDA regarding soft tissue fillers and with these changes the FDA suggests:
- “Make sure that you are familiar with the anatomy at and around the site of injection, keeping in mind that blood vessel anatomy
can vary among patients.”
The AccuVein AV400 allows the clinician to view a roadmap of the vasculature that would typically be unseen, allowing aestheticians to avoid veins entirely or work around them. The use of vein illumination can help physicians be more careful during injectable procedures and help them to more easily follow the FDA’s newly suggested guidelines for administering fillers in the soft tissue of the face.
Source: FDA
